Selection for and initiation of continuous subcutaneous insulin infusion. Proceedings from a workshop

Ragnar Hanas1

  • 1Department of Pediatrics, Uddevalla Hospital, Sweden. ragnar.hanas@bll.se

Hormone Research
|April 30, 2002
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is increasingly used for children and adolescents with diabetes. This safe and effective method can improve glycemic control, lower HbA1c, and reduce severe hypoglycemia and hospital admissions.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Continuous subcutaneous insulin infusion (CSII) has over 20 years of use in pediatric diabetes management.
  • Increasing interest in insulin pump therapy for young children and adolescents is noted, with usage rising in countries like Sweden.
  • Indications for pump therapy are shifting from purely medical issues to include quality of life improvements.

Purpose of the Study:

  • To evaluate the safety and efficacy of CSII in pediatric patients.
  • To assess the impact of CSII on glycemic control (HbA1c) and hypoglycemia risk.
  • To explore the practical aspects and acceptance of CSII in children and adolescents.

Main Methods:

  • CSII initiated via inpatient or outpatient 'pump school' with parental training.
  • Adjustment of total daily insulin dose, often reduced by 15-20% compared to injections.
  • Use of rapid-acting insulin analogues and specific insulin concentrations based on basal rate.

Main Results:

  • CSII is associated with lowered HbA1c and reduced risk of severe hypoglycemia.
  • Successful use of CSII in preventing recurrent diabetic ketoacidosis admissions.
  • Daily insulin requirements are typically decreased with CSII compared to injection therapy.

Conclusions:

  • CSII is a well-accepted and safely manageable treatment option for children and adolescents with diabetes.
  • The technique can be initiated with a manageable extra effort from healthcare teams and families.
  • Quality of life and improved clinical outcomes are key drivers for the increasing adoption of CSII in pediatric diabetes care.

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...
Two-Compartment Open Model: IV Infusion01:15

Two-Compartment Open Model: IV Infusion

A two-compartment model is a vital tool in pharmacokinetics, providing an essential understanding of drug behavior, especially for those administered via zero-order intravenous infusion. This model outlines two compartments: the central compartment, where elimination occurs, and the peripheral compartment.
The model illustrates the decrease in plasma drug concentration from the central compartment with a specific equation. It shows that under steady-state conditions, the drug's input rate...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...